Anaplasma phagocytophilum: Equine Granulocytic Anaplasmosis, Tick-Borne Diagnosis and Management

Etiology and Taxonomy

Anaplasma phagocytophilum is a Gram-negative, obligate intracellular bacterium belonging to the family Anaplasmataceae, order Rickettsiales. The organism infects neutrophils and, less frequently, eosinophils and basophils in a wide range of mammalian hosts, including horses, dogs, cats, ruminants, and humans. In equids, the infection is termed equine granulocytic anaplasmosis (EGA). The bacterium is transmitted primarily by ixodid ticks of the genus Ixodes, with Ixodes scapularis and Ixodes pacificus serving as principal vectors in North America and Ixodes ricinus in Europe [1]. The pathogen exhibits a complex life cycle involving a tick vector and a vertebrate reservoir, with small mammals such as rodents and deer acting as natural reservoirs. Horses are considered accidental hosts but can develop clinically significant disease.

The organism was historically classified as Ehrlichia equi and later Anaplasma phagocytophila before the current nomenclature was established through phylogenetic analyses of 16S rRNA and groEL gene sequences. The bacterium resides within membrane-bound vacuoles (morulae) in the cytoplasm of infected neutrophils, evading host immune responses through antigenic variation and modulation of neutrophil apoptosis.

Epidemiology and Tick-Borne Transmission

Equine granulocytic anaplasmosis occurs in temperate regions where Ixodes ticks are endemic. The geographic distribution mirrors that of Lyme borreliosis, as both pathogens share the same tick vectors. In North America, cases are reported predominantly in the northeastern, mid-Atlantic, and upper Midwestern United States, as well as parts of California. In Europe, the disease is recognized in the United Kingdom, Scandinavia, Central Europe, and the Mediterranean basin [1].

Transmission occurs when an infected tick feeds on a susceptible horse. Nymphal and adult female ticks are the primary life stages responsible for transmission. The tick must feed for at least 24 to 48 hours before bacterial transmission is efficient, as A. phagocytophilum replicates in the tick salivary glands and requires a feeding period for reactivation. Co-feeding transmission between infected and uninfected ticks on the same host has also been documented, which may facilitate local amplification without systemic infection in the host.

Seasonal patterns reflect tick activity, with most equine cases occurring in spring, late summer, and autumn. The incubation period in experimentally infected horses ranges from 5 to 14 days. Seroprevalence studies indicate that exposure is common in endemic areas, with subclinical infections occurring frequently. However, clinical disease is more likely in naive adult horses or those under stress.

Clinical Signs and Pathophysiology

The clinical presentation of EGA is variable, ranging from subclinical infection to severe systemic illness. The hallmark of the disease is fever, often exceeding 39.5 degrees Celsius, accompanied by lethargy, anorexia, and limb edema. Other common signs include petechiation, icterus, ataxia, and reluctance to move. Thrombocytopenia and leukopenia are consistent hematologic findings [1].

The pathophysiology is driven by the bacterium's tropism for neutrophils. After entering the bloodstream via tick saliva, A. phagocytophilum binds to neutrophil surface receptors, including P-selectin glycoprotein ligand-1 (PSGL-1), and is internalized. The bacterium survives within a host-derived vacuole by inhibiting phagolysosomal fusion and superoxide production. Infected neutrophils exhibit altered adhesion, migration, and apoptosis, leading to vascular inflammation and endothelial damage. This results in increased vascular permeability, which manifests as dependent edema, particularly of the distal limbs and ventral abdomen.

Thrombocytopenia arises from immune-mediated destruction and consumption, while leukopenia reflects sequestration and apoptosis of infected neutrophils. Hepatic enzyme elevations, particularly sorbitol dehydrogenase and gamma-glutamyl transferase, indicate mild to moderate hepatocellular injury. Bilirubinemia may occur due to hemolysis or cholestasis.

Neurologic signs, such as ataxia and hyperesthesia, are less common but can occur due to meningeal inflammation or vasculitis. Myopathy and rhabdomyolysis have been reported in severe cases, likely secondary to fever and recumbency.

Pathology and Postmortem Findings

Gross pathologic findings in fatal cases are nonspecific but include generalized icterus, petechial hemorrhages on serosal surfaces, splenomegaly, and hepatomegaly. Histopathologic examination reveals perivascular lymphohistiocytic infiltrates in multiple organs, including the brain, heart, liver, and kidneys. The hallmark microscopic lesion is the presence of intracytoplasmic morulae within neutrophils in blood smears and tissue sections. Morulae appear as basophilic, mulberry-like inclusions measuring 1.5 to 4.0 micrometers in diameter.

In the spleen, lymphoid depletion and erythrophagocytosis are observed. The liver shows periportal hepatitis with bile stasis. Renal glomeruli may exhibit mesangial proliferation and immune complex deposition. Pulmonary edema and interstitial pneumonia are occasionally noted.

Diagnostic Approaches

Hematology and Cytology

The initial diagnostic step in a suspect case is a complete blood count and examination of a Giemsa- or Wright-stained blood smear. Thrombocytopenia (platelet count below 100,000 per microliter) and leukopenia (white blood cell count below 5,000 per microliter) are characteristic. The presence of morulae in neutrophils is diagnostic but sensitivity is moderate, as morulae may be scarce or absent in early or antibiotic-treated cases. Examination of buffy coat preparations can increase sensitivity.

Serology

Serologic testing using indirect immunofluorescence assay (IFA) or enzyme-linked immunosorbent assay (ELISA) detects antibodies against A. phagocytophilum. A four-fold rise in titer between acute and convalescent samples (collected 2 to 4 weeks apart) confirms recent infection. However, serology cannot distinguish active from past infection, and cross-reactivity with other Anaplasmataceae (e.g., Anaplasma marginale, Ehrlichia canis) can occur. In endemic areas, baseline seroprevalence may be high, complicating interpretation.

Molecular Diagnostics

Polymerase chain reaction (PCR) targeting the 16S rRNA gene, msp2 (p44) gene, or groEL gene is the gold standard for confirming active infection. PCR can detect bacterial DNA in whole blood, buffy coat, or tissue samples. Real-time PCR assays offer high sensitivity and specificity, with detection limits as low as 10 copies per reaction. PCR is particularly useful in the acute phase when morulae are absent and serology is negative. Quantitative PCR can monitor bacterial load during treatment.

Diagnostic Workflow

The following Mermaid diagram illustrates a recommended diagnostic algorithm for suspect equine granulocytic anaplasmosis.

flowchart TD
    A[Equine patient with fever, lethargy, limb edema], > B{Blood smear for morulae}
    B, >|Positive| C[Confirm with PCR or serology]
    B, >|Negative| D[Perform PCR on whole blood]
    D, > E{PCR result}
    E, >|Positive| F[Confirm EGA diagnosis]
    E, >|Negative| G[Consider serology: acute and convalescent]
    G, > H{Four-fold titer rise?}
    H, >|Yes| F
    H, >|No| I[Re-evaluate for other tick-borne diseases]
    C, > F
    F, > J[Initiate treatment and supportive care]

Differential Diagnoses

Equine granulocytic anaplasmosis must be differentiated from other febrile illnesses in horses, including equine piroplasmosis (caused by Babesia caballi and Theileria equi), equine infectious anemia, leptospirosis, and viral encephalitides such as West Nile virus infection. Co-infections with Borrelia burgdorferi or Ehrlichia species are possible in tick-exposed horses and may complicate the clinical picture. For a broader perspective on tick-borne pathogens in companion animals, see the article on Tick-Borne Diseases in Dogs: Comprehensive Review of Common Pathogens, Clinical Syndromes, and Management.

Treatment and Therapeutic Management

The treatment of choice for EGA is oxytetracycline at a dose of 7 mg/kg intravenously once daily for 5 to 7 days, or doxycycline at 10 mg/kg orally twice daily for 7 to 14 days [1]. Tetracyclines inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit, effectively clearing the infection. Clinical improvement is typically observed within 24 to 48 hours of initiating therapy.

Supportive care is essential in severe cases. Intravenous fluid therapy corrects dehydration and electrolyte imbalances. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine (1.1 mg/kg intravenously) are used to reduce fever and inflammation, but caution is warranted in horses with renal compromise or gastrointestinal ulceration. Corticosteroids are generally contraindicated due to the risk of immunosuppression and exacerbation of infection.

In horses with severe thrombocytopenia or bleeding tendencies, platelet transfusions may be considered, though availability is limited. Recumbent horses require intensive nursing care, including padded stalls, frequent turning, and eye protection.

Antimicrobial resistance to tetracyclines has not been reported in A. phagocytophilum, but treatment failures can occur if therapy is initiated late or if the horse has concurrent infections. Relapses are uncommon but may occur if treatment duration is insufficient.

Prevention and Control

Prevention of EGA relies on reducing tick exposure through integrated pest management strategies. Environmental measures include pasture rotation, brush clearing, and application of acaricides to vegetation. Topical acaricides approved for horses, such as permethrin-based sprays or spot-on formulations, can be applied during tick season. Daily tick checks and prompt removal of attached ticks reduce transmission risk, as the bacterium requires prolonged feeding for transmission.

No commercial vaccine is currently available for EGA. Research into recombinant outer membrane protein vaccines is ongoing but has not yet yielded a licensed product. In endemic areas, owners should be educated about the seasonal and geographic risk.

Quarantine of newly introduced horses from endemic regions is not routinely recommended but may be considered for horses with unknown tick exposure history. Serologic screening of incoming horses can identify carriers, though persistent infection is rare in equids.

For a discussion of tick-borne disease management in other livestock species, refer to the article on Anaplasma phagocytophilum in Livestock and Companion Animals: Diagnostics and Tick-Borne Epidemiology.

Prognosis

The prognosis for horses with EGA is generally favorable with prompt diagnosis and appropriate antimicrobial therapy. Mortality rates are low, typically less than 5 percent, and most horses recover fully within 1 to 2 weeks. Poor prognostic indicators include severe thrombocytopenia (platelet count below 20,000 per microliter), neurologic signs, recumbency, and delayed treatment. Secondary infections, such as pneumonia or cellulitis, can complicate recovery.

Conclusion

Equine granulocytic anaplasmosis is an important tick-borne bacterial disease of horses caused by Anaplasma phagocytophilum. The disease presents with fever, lethargy, limb edema, and hematologic abnormalities. Diagnosis relies on blood smear cytology, PCR, and serology. Treatment with oxytetracycline or doxycycline is highly effective. Prevention centers on tick control and owner education. As tick ranges expand due to climate change and habitat alteration, the geographic footprint of EGA is likely to widen, underscoring the need for continued surveillance and diagnostic preparedness.

References

[1] Bogdan AM, Mitrea IL, Ionita M. Equine Granulocytic Anaplasmosis: A Systematic Review and Meta-Analysis on Clinico-Pathological Findings, Diagnosis, and Therapeutic Management. Vet Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38922016/